New 'smart' nanotherapeutics can deliver drugs directly to the pancreas
A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children's Hospital Boston has developed "smart" injectable nanotherapeutics that can be programmed to selectively deliver drugs to the cells of the pancreas.
Read more ...
Chemotherapy may influence leukemia relapse
The chemotherapy drugs required to push a common form of adult leukemia into remission may contribute to DNA damage that can lead to a relapse of the disease in some patients, findings of a new study suggest.
Read more ...
Study finds statin costs 400 percent higher in US compared to UK
In the United States, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who have private insurance is approximately 400 percent higher than comparable costs paid by the government in the United Kingdom.
Read more ...
Benefits of statin therapy may extend beyond lowering lipids
People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.
Read more ...
Missing trial data threatens the integrity of medicine
Missing clinical trial data can harm patients and lead to futile costs to health systems, warn experts as part of an in-depth BMJ review of the matter. Missing data is a serious problem in clinical research. It distorts the scientific record, so that clinical decisions cannot be based on the best evidence.
Read more ...
Hepatitis C virus hijacks liver microRNA
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Read more ...
Ovarian cancer study proves drug delays disease progression
Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.
Read more ...
